Section 1: Introductory Statements and Governance

1ISG-013

ECONOMIC IMPACT OF ORPHAN DRUGS USED IN PAEDIATRIC PATIENTS ATTENDING HOSPITAL OUTPATIENT PHARMACY AND DAY HOSPITAL

1ISG-012

THE ROLE OF THE PHARMACIST IN CHOOSING THE CENTRAL VENOUS ACCESS DEVICE FOR THE PREVENTION OF COMPLICATIONS: AN EXAMPLE OF BUDGET IMPACT ANALYSIS

1ISG-007

BIOSIMILAR OF INFLIXIMAB: DOES THE PENETRATION RATE MEET EXPECTATIONS? APPRAISAL IN A CENTRAL PURCHASING OFFICE

1ISG-006

CONTAMINATION OF THE BLISTER PACKS BY POMALIDOMIDE AFTER USE IN CLINICAL SITUATION

1ISG-020

MARKET ACCESS IN THE EU, DO WE HAVE ENOUGH EVIDENCE?

1ISG-009

ECONOMIC IMPACT OF AFLIBERCEPT OPTIMISATION FOR THE TREATMENT OF EYE-RELATED CONDITIONS

1ISG-003

COST SAVING IN ANTIRETROVIRAL THERAPY THROUGH BREAKING FIXED-DOSE COMBINATION AND SWITCH TO GENERIC FORMULATIONS

1ISG-002

EFFECTIVENESS OF ANGIOTENSIN RECEPTOR BLOCKER IN HOSPITALISED PATIENT

1ISG-014

ISO 9001 CERTIFICATION: CUSTOMER FOCUS

1ISG-011

DEVELOPMENT OF A PREDICTIVE MODEL FOR ESTIMATING FUTURE DRUG EXPENSES

1ISG-008

ECONOMIC IMPACT OF THE USE OF BIOSIMILAR INFLIXIMAB IN A SECOND-LEVEL HOSPITAL

1ISG-005

A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB VERSUS DOCETAXEL FOR ADVANCED NONSQUAMOUS NON-SMALL-CELL LUNG CANCER IN SECOND LINE IN A HEALTHCARE SETTING

Pages